ARTICLE | Company News
Avanir, OptiNose deal
July 15, 2013 7:00 AM UTC
OptiNose granted Avanir exclusive North American rights to develop and commercialize its acute migraine product, OptiNose sumatriptan ( AVP-825). OptiNose received $20 million up front and is eligibl...